Home
Subscription
April 2024 issue
April 1, 2024 issue
March 2024 issue
February 2024 issue
January 2024 issue
BACK ISSUES
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
|
2018 Issues
December 2018 Issue
• Feature: For Those Without a Voice or Choice – A Gift of Life
• New Drug Review: Fremanezumab-vfrm (Ajovy)
• Appreciation
• Index for Volume 13, 2018
November 2018 Issue
• Feature: Nicotine, Cigarettes, JUUL, Chantix, FDA Talk, Chain Pharmacy Hypocrisy, and Boards of Pharmacy Inertia
• New Drug Review: Baloxavir marboxil (Xofluza)
October 2018 Issue
• Feature: The Drug Pricing Blame Games
• New Drug Review: Erenumab-aooe (Aimovig)
September 2018 Issue
• Feature: Reducing Drug Costs – PBMs are Not Needed and Should Not be Used!
August 2018 Issue
• Feature: THE CORPORATE DESTRUCTION OF HEALTH CARE: Part 2
• New Drug Review: Betrixaban (Bevyxxa)
July 2018 Issue
• Feature: THE CORPORATE DESTRUCTION OF HEALTH CARE: Part 1, And Health Professionals are Letting It Happen!
• Table: New Therapeutic Agents Marketed in the United States in 2017
June 2018 Issue
• Feature: Chain Pharmacists of America (CPOA): Part 2
• Why CVS Loves ObamaCare
• New Drug Review: Delafloxacin meglumine (Baxdela)
May 2018 Issue
• Feature: Chain Pharmacists of America (CPOA)
• New Drug Review: Ertugliflozin L-pyroglutamic acid (Steglatro
April 2018 Issue
• Feature: National Pharmacy Associations Announce Historic Merger!
• New Drug Review: Wonder Drug Inspires Deep, Unwavering Love of Pharmaceutical Companies
March 2018 Issue
• Feature: Merger Mania – Bigger Isn't Better!
• New Drug Review: Semaglutide (Ozempic)
February 2018 Issue
• Feature: Independent Pharmacies and the Fight for Survival
January 2018 Issue
• Feature: The FTC Must Prevent CVS from Acquiring Aetna, and Require CVS to Divest Caremark!
| |
